Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

non-small cell lung cancer, early stage 1179O THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT: A WAY TO BRIDGE NON-SMALL CELL LUNG CANCER MOLECULAR CHARACTERISTICS AND CLINICAL DATA S. Peters 1 , O. Dafni 2 , L. Bubendorf 3 , P. Meldgaard 4 ,K.O’Byrne 5 , A. Wrona 6 , W. Weder 7 , M. Canela 8 , S. Malatesta 9 , J. Vansteenkiste 10 , A-M. Dingemans 11 , M. Nicolson 12 , S. Savic 13 , P. Baas 14 , R. Peck 15 ,S.Lu 16 ,E.Smit 17 , E. Jantus-Lewintre 18 , R. Rosell 19 , R.A. Stahel 20 1 Multidisciplinary Oncology Center, Lausanne Cancer Center, Centre Hospitalier Universitaire Vaudois, Lausanne, SWITZERLAND, 2 Frontier Science Foundation-Hellas, Athens, GREECE, 3 Division of Cytology, Institute for Pathology, University Hospital Basel, Basel, SWITZERLAND, 4 Department of Oncology, Aarhus University Hospital, Aarhus, DENMARK, 5 HOPE Directorate, St James’s Hospital, Dublin, IRELAND, 6 Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, POLAND, 7 Division of Thoracic Surgery, University Hospital Zurich, Zurich, SWITZERLAND, 8 Surgery, Vall d’Hebron University Hospital, Barcelona, SPAIN, 9 Anatomia Patologica, Ospedale Clinicizzato, Chieti, ITALY, 10 Respiratory Oncology, University Hospital Leuven, Leuven, BELGIUM, 11 Pulmonology, Maastricht University Medical Centre, Maastricht, NETHERLANDS, 12 Medical Oncology, Aberdeen Royal Infirmary, Aberdeen, UNITED KINGDOM, 13 Pathology, Institute for Pathology, University Hospital Basel, Basel, SWITZERLAND, 14 Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 15 University Hospital South Manchester and The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 16 Shanghai Lung Tumor Clinic Center, Shanghai Chest Hospital, Shanghai, CHINA, 17 Pulmonology, Vrije Universiteit Medical Center, Amsterdam, NETHERLANDS, 18 Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, SPAIN, 19 Medical Oncology Service, Catalan Institute of Oncology, Badalona (Barcelona), SPAIN, 20 Clinic of Oncology, University Hospital Zurich, Zurich, SWITZERLAND Background: The Lungscape project aims at building a virtual biobank to facilitate an international high-quality analysis of large numbers of tumors for molecular alterations linked to clinical and biological characteristics captured in the iBiobank. Methods: Retrospective radically resected stage I-III non-small cell lung cancer cases from 15 ETOP centers, with mandatory comprehensive clinical annotations including at least 2 years of FU have been reviewed and captured. Results: This first set of 1614 cases was enriched in adenocarcinoma (61.8%), with 28.8% of squamous and 4.9% of large cell histologies. Median age is 65 yrs, 37.6% are women, and respectively 13.9%, 33.5% and 49.6% are never, current and former smokers. Stage distribution is: IA 23.7%, IB 25.8%, IIA 16.4%, IIB 11.6%, IIIA 20.8%, IIIB 1.7%. At last FU, 52.8% of patients were still alive, with a median FU of 5.3 yrs. PFS No. of patients 5 years (95% C.I.) Median (mos) (95% C.I.) TOTAL 1614 46 (43.3, 48.6) 49.0 ( 43.9, 55.2) Stage Ia 382 64.5 (59.1, 60.5) NR Ib 417 55.4 (50.3, 60.5) 78.0 IIa 264 44.8 (38.4, 51.3) 46.9 IIb 187 39.2 (31.6, 46.8) 33.7 IIIa 335 20.0 (15.2, 24.8) 17.5 IIIb 28 11.9 (0.0, 25.3) 10.1 OS 1614 52.0 (49.3, 54.7) 64.2 (57.3, 76.9) Stage Ia 382 70.0 (64.9, 75.2) NR Ib 417 60.6 (55.5, 65.7) NR IIa 264 50.5 (43.8, 57.1) 62.2 IIb 187 43.7 (36.0, 51.4) 43.3 IIIa 335 29.3 (23.9, 34.7) 29.0 IIIb 28 10.3 (0.0, 27.1) 20.2 Conclusion: This is the first large-scale series based on 7th TNM classification reporting on OS and PFS in the context of European standards of care. These data confirm the discriminative capacity of the 7 th TNM with a potentially somewhat superior outcome. Histologies other than adenocarcinoma are currently actively being captured. Complete data including PFS and TTP - never reported before - as well as OS based on the expected 2400 patients correlated to stage, gender, smoking status, histology and age will be provided. This complete clinical dataset will be Annals of Oncology 23 (Supplement 9): ix385–ix388, 2012 doi:10.1093/annonc/mds407 invaluable to investigate the impact of molecular characteristics on outcome. It will allow building future hypothesis for prospective evaluation of new treatment strategies and help in the development of a molecularly refined TNM. Disclosure: All authors have declared no conflicts of interest. 1180PD EXPRESSION OF HYPOXIA-INDUCED FACTOR 1α AND GLUCOSE TRANSPORTER 1 CORRELATES WITH [18F]-FLUORO-2-DEOXY-GLUCOSE UPTAKE ON POSITRON EMISSION TOMOGRAPHY AND TUMOR AGGRESSIVENESS IN DIFFERENT HISTOLOGIC SUBTYPES OF LUNG ADENOCARCINOMAS Y. Miyata, T. Furukawa, Y. Tsutani, T. Mimae, K. Misumi, T. Yoshiya, Y. Ibuki, M. Okada Surgical Oncology, Hiroshima University, Hiroshima, JAPAN Background: High maximal standardized uptake values (SUVmax) on [18F]-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) are associated with inferior survival in lung adenocarcinoma. However, the exact mechanisms are unknown. Here, we investigated the biological mechanisms underlying FDG uptake in different subtypes of adenocarcimomas. Methods: This retrospective study included 287 patients with adenocarcinoma (166 with Stage IA). The patients underwent systematic tumor resection at Hiroshima University Hospital from January 2007 to December 2011, at the latest, 4 weeks after FDG-PET. The SUVmax values for primary lesions were calculated based on FDG uptake. Tumors were subdivided according to each morphologic growth pattern. The expression of hypoxia-inducible factor 1α (HIF1α) and glucose transporter 1 (GLUT1) was evaluated in 70 patients with 147 histologic subtypes using immunostaining. Results: There were significant differences in SUVmax and disease-free survival (DFS) among different histologic subtypes. Mean SUVmax and 5-year DFS were 0.90 and 100% in is situ (n = 41), 1.1 and 100% in minimally invasive (n = 5), 1.8 and 94.3% in lepidic (n = 66), 3.9 and 75.2% in papillary (n = 136), 5.4 and 91.7% in acinar (n = 26), and 7.6 and 71.6% in solid (n = 13) predominant subtypes. HIF1α and GLUT1, and GLUT1 and SUVmax were significantly correlated (p < 0.001 for both) in adenocarcinoma. Moreover, the expressions of HIF1α and GLUT1 correlated with various clinicopathological factors relating to malignancy, such as pathological stage (I vs. II + III; p = 0.014), lymph node metastasis (p = 0.037), pleural invasion (p = 0.0093), lymphatic invasion (p < 0.001), and venous invasion (p < 0.001). GLUT1 and SUVmax were jointly associated with DFS (p = 0.0098 and p < 0.001, respectively in adenocarcinoma). There were significant differences in HIF1α and GLUT1 expression among different histologic subtypes. Mean HIF1α and GLUT1score were 0 and 0.15 in is situ (n = 13), 0.03 and 0.11 in lepidic (n = 36), 0.19 and 1.0 in papillary (n = 52), 0.47 and 1.2 in acinar (n = 34), 0.11 and 1.6 in micropapillary (n = 9), and 2.3 and 3.0 in solid (n = 3) subtypes. Conclusions: In different histologic subtypes of lung adenocarcinomas, HIF1α-induced GLUT1 expression might explain high FDG uptake on PET and correlate with poor prognosis. Disclosure: All authors have declared no conflicts of interest. 1181PD RANDOMIZED PHASE II STUDY OF ADJUVANT CHEMOTHERAPY WITH S-1 VERSUS CDDP + S-1 IN RESECTED STAGE II-IIIA NON-SMALL-CELL LUNG CANCER (WJOG4107) H. Yoshioka1 , Y. Iwamoto2 , S. Ito3 , T. Yamanaka4 , H. Tada5 , M. Yoshimura6 , I. Okamoto7 , I. Yoshino8 , K. Nakagawa7 , Y. Nakanishi9 1 2 Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, JAPAN, Medical Oncology, Hiroshima City Hospital, Hiroshima, JAPAN, 3 Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, JAPAN, 4 Clinical Research Center, National Cancer Research Center, East Hospital, Kashiwa, JAPAN, 5 General Thoracic Surgery, Osaka City General Hospital, Osaka, JAPAN, 6 7 Thoracic Surgery, Hyogo Cancer Center, Akashi, JAPAN, Medical Oncology, Kinki University School of Medicine, Osakasayama, JAPAN, 8 General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, JAPAN, 9 Research Institute for Diseases of The Chest, Kyushu University Hospital, Fukuoka, JAPAN Background: Postoperative cisplatin doublet chemotherapy benefits patients with completely resected stage II-IIIA non-small-cell lung cancer (NSCLC). S-1 is an oral fluorinated pyrimidine formulation that combines tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1 and © European Society for Medical Oncology 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com abstracts
widely used by single agent or platinum doublet for advanced NSCLC in Japan. This phase II trial assessed the efficacy and safety of S-1 and cisplatin plus S-1 for adjuvant chemotherapy. Methods: From September 2007 to Dec 2009, 200 patients with completely resected stage II and IIIA (exclude multi-station N2 cases) NSCLC were randomized to receive either oral S-1 (40 mg/m2 twice per day) for consecutive 2 weeks repeated every 3 weeks for 1 year or cisplatin (60 mg/m2 day1) plus oral S-1 (40 mg/m2 twice per day) for consecutive 2 weeks repeated every 3 weeks for 4 cycles within 8 weeks after surgery. Main inclusion criteria were no prior chemotherapy or radiotherapy, ECOG PS 0-1, an age of less than 75 years, and an adequate organ function. Stratification factors included histology, stage and institutions. Primary endpoint was relapse free survival rate on 2 years and secondary endpoints were overall survival (OS) and toxicity. Results: Patient demographics were well balanced between the arms in terms of sex, age, histologic type and stage. 52.6% of patients in S-1 arm and 76.7% in cisplatin plus S-1 arm were completed planned administration. Relapse free survival rate on 2 years was 65.6% (95% confidence interval, 55.3-74.0%) in the S-1 arm and 58.1% (95% confidence interval, 47.7-67.2%) in the cisplatin plus S-1 arm. OS were not matured in the both arms. Though the rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, nausea, and vomiting were more frequent in the cisplatin plus S-1 arm, there were no treatment related deaths in the both groups. Conclusion: Both S-1 monotherapy and cisplatin plus S-1 are feasible as adjuvant chemotherapy for completed resected NSCLC. Disclosure: I. Yoshino: Research Funds from Taiho Pharmaceutical Co. and Chugai Pharmaceutical Co.All other authors have declared no conflicts of interest. 1182P IMMUNOGENICITY AND SAFETY OF THE PRAME CANCER IMMUNOTHERAPEUTIC IN NON-SMALL CELL LUNG CANCER (NSCLC): PHASE I DOSE ESCALATION STUDY J. Pujol 1 ,T.DePas 2 , A. Rittmeyer 3 , B. Kubisa 4 , E. Vallieres 5 , E. Levchenko 6 , B. Salaun 7 , N. Vanhoutte 8 , M. Debois 8 , V. Brichard 9 1 Thoracic Oncologic Unit, Montpellier Academic Hospital, Hospital Arnaud De Villeneuve, Montpellier, Montpellier, FRANCE, 2 Medical Oncology, European Institute of Oncology, Milan, ITALY, 3 Lungenfachklinik Immenhausen, Lungenfachklinik Immenhausen, Immenhausen, GERMANY, 4 Thoracic Surgery, Pomeranian Medical University, Szczecin, POLAND, 5 Thoracic Oncology, Swedish Cancer Institute, Seattle, WA, UNITED STATES OF AMERICA, 6 Thoracic Oncology, Petrov Research Institution of Oncology, St. Petersburg, RUSSIAN FEDERATION, 7 R&D DAP Cancer, GlaxoSmithKline Biologicals, Rixensart, BELGIUM, 8 Immunotherapeutics, GlaxoSmithKline Biologicals, Rixensart, BELGIUM, 9 Immunotherapeutics BU, GlaxoSmithKline Biologicals, Rixensart, BELGIUM Introduction: Adjuvant chemotherapy (CT) is the standard treatment for stage II– IIIA NSCLC, but is debated for stage IB. As not all patients (pts) are eligible for CT and many of them relapse, alternative therapies are needed. The PRAME tumor antigen, expressed frequently in NSCLC and at lower levels in few normal cells, offers an attractive target for active immunization. Moreover, while most NSCLC tumors expressing the antigen MAGE-A3 are PRAME positive, 45% of PRAME-expressing NSCLC do not express MAGE-A3. This dose-escalation phase I open study aimed at determining the optimal dose of the PRAME cancer immunotherapeutic (PRAME recombinant protein (recPRAME) with AS15 immunostimulant) by evaluating its safety and immunogenicity in NSCLC pts. Methods: Pts with PRAME-positive resected stage IB-IIIA NSCLC were enrolled in 3 consecutive cohorts to receive up to 13 injections of recPRAME (20 µg, 100 µg, and 500 µg) with AS15 (fixed dose) over approximately 2 years. Adverse events (AEs), including pre-defined dose-limiting toxicity (DLT), were recorded throughout the study. The anti-PRAME humoral and cellular responses were assessed post-dose 4 by ELISA and flow cytometry (PRAME-specific T-cells producing both IFNγ and TNFα), respectively. Results: 60 pts were treated in the study (18, 18, 24 pts received 20, 100, 500 µg recPRAME, respectively). AEs were mostly grade 1/2. No grade 3/4 AEs considered by the investigator to be causally related were reported. One grade 2 serious AE causally related to PRAME administration was reported. No DLTs were reported. Immunogenicity results are shown in the table. Conclusions: The PRAME cancer immunotherapeutic was well-tolerated and elicited similar humoral responses in all 3 cohorts. A trend for an increased cellular response was observed with increasing dose of recPRAME. Thus, the highest dose was selected for further clinical development. Immunogenicity post-dose 4 (ATP population). Annals of Oncology Cohort (recPRAME dose) 1 (20 µg) 2 (100 µg) 3 (500 µg) Humoral responders, n/N* 10/10 11/11 19/19 CD4+ T-cell responders, n/N* (%) 3/9 (33%) 6/10 (60%) 12/15 (80%) CD8+ T-cell responders, n/N* (%) 0/8 (0%) 0/10 (0%) 0/13 (0%) N, number of patients enrolled into each group; * number of patients with pre and post-vaccination results; n, number of responders; ATP, according-to-protocol Funding: GSK Biologicals Disclosure: J. Pujol: Honorarium study coordination as only conflict of interest. B. Kubisa: I am the Principal Investigator of this study at my institution. E. Vallieres: I am a consultant for GLAXOSMITHKLINE BIOLOGICALS and a member of the PRAME NSCLC Global Development Advisory Board. B. Salaun: Currently employed by GSK Vaccines as a scientist. N. Vanhoutte: Employee of GlaxoSmithKline Biologicals. M. Debois: Employee of GlaxoSmithKline Biologicals. V. Brichard: GSK employee. All other authors have declared no conflicts of interest. 1183P USE OF ADJUVANT CHEMOTHERAPY (CT) AND RADIOTHERAPY (RT) IN INCOMPLETELY RESECTED (R1) EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC): A EUROPEAN SURVEY CONDUCTED BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) YOUNG ONCOLOGISTS COMMITTEE R. Califano, on behalf of the Young Oncologists Committee of the European Society for Medical Oncology Department of Medical Oncology, The Christie NHS Foundation Trust & University Hospital of South Manchester NHS Foundation Trust, Manchester, UNITED KINGDOM Background: Early stage NSCLC is potentially curable with radical surgery. Cisplatin-based adjuvant CT improves survival and is recommended in the ESMO guidelines for stage II-III completely resected NSCLC. There is limited evidence to guide the use of adjuvant CT and RT in incompletely resected (R1) early stage NSCLC. Design and objective: A European survey of oncologists treating lung cancer was conducted to evaluate the use of adjuvant CT and RT for R1-resected NSCLC and to identify factors influencing treatment decisions. Demographics were collected and outcomes such as clinical stage, regimens, cycles planned, radiotherapy site, multidisciplinary management and discussion about inconclusive evidence with the patient were analyzed. Logistic regression model was used to detect statistical association and to estimate Odds Ratio; Cochrane-Armitage test was used to detect trend. Results: 768 surveys were collected from 41 European countries between January to April 2012. 82.9% of participants were medical oncologists; 49.3% ESMO members; 37.1% based in a University Hospital; 32.6% practicing oncology for more than 15 years and 81.4% active in research. 91.4% of participants prescribed adjuvant CT. Prescription according to stage: IA/IB/IIA/IIB/IIIA = 13.3%/44.8%/83.9%/90.5%/ 94.5%, respectively. Most common CT regimens were: Cisplatin/Vinorelbine (81.2%), Cisplatin/Gemcitabine (42.9%), Carboplatin/Vinorelbine (31.6%), Carboplatin/ Paclitaxel (31%) and Carboplatin/Gemcitabine (26.7%). Number of cycles planned: 3/ 4/6 = 7.5%/78.1%/14.5%, respectively. 85% discussed limited clinical evidence with the patient. 48.3% of participants prescribed adjuvant RT. Among these, RT to the surgical bed and for pN2 disease was prescribed by 85.1% and 84.8%, respectively. Most common RT regimens for surgical bed: 60 Gy in 30 fractions (Fx) (45.6%), 54 Gy in 27-30 Fx (29.6%), 50 Gy in 20 Fx (23.4%) and 52.5 Gy in 20 Fx (3.6%). Most common RT regimens for pN2 disease: 60 Gy in 30 Fx (35.2%), 54 Gy in 27-30 Fx (34.1%), 50 Gy in 20 Fx (24.1%) and 50 Gy in 25 Fx (4.8%). Conclusions: This European survey indicates that adjuvant CT and RT for incompletely resected (R1) NSCLC are commonly used in clinical practice despite limited evidence. Prospective trials for R1-resected NSCLC are necessary to clarify optimal management. Acknowledgments: ESMO Young Oncologists Committee: R. Califano, The Christie NHS Foundation Trust, Manchester, United Kingdom; E. Martinelli, Second University of Naples, Naples, Italy; V. Guarneri, University of Modena and Reggio Emilia, Modena, Italy; S. Banerjee, Royal Marsden Hospital, London, United Kingdom; D. Olmos Hidalgo, National Cancer research Centre (CNIO), Madrid, Spain; S. Postel-Vinay, Institute of Cancer Research ICR, London, United Kingdom; K. Jordan, University Hospital of Halle, Halle, Germany; M. Karamouzis, School of Medicine, University of Athens, Athens, Greece; K. Kamposioras, University Hospital of Larissa, Larissa, Greece; M. Preusser, Medical University of Vienna, Vienna, Austria; E. de Azambuja, Institute Jules Bordet, Brussels, Belgium; M. Hutka, Royal Marsden Hospital, London, United Kingdom. ix386 | Abstracts Volume 23 | Supplement 9 | September 2012
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240:
considered sufficient to give an 80
Page 241 and 242:
721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244:
after Gem-based therapy. The additi
Page 245 and 246:
735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248:
validate the revised AJCC 7th stagi
Page 249 and 250:
Results: Among 862 MM we identified
Page 251 and 252:
Results: Frequently reported advers
Page 253 and 254:
gastric cancer patients with CNS me
Page 255 and 256:
discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260:
abstracts genitourinary tumors, non
Page 261 and 262:
787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264:
patient preference for P over S, an
Page 265 and 266:
798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268:
Hb, PS and LM. Median PFS for patie
Page 269 and 270:
may have led to reduced dose and sh
Page 271 and 272:
Results: 1,622 patients were identi
Page 273 and 274:
RCC) was designed to address an unm
Page 275 and 276:
Patients and methods: This is a sin
Page 277 and 278:
treatment at week 4, and week 12 by
Page 279 and 280:
effective in second or further line
Page 281 and 282:
Conclusions: In pts with RCC treate
Page 283 and 284:
using Drug inCode ® pharmacogeneti
Page 285 and 286:
Table: 857P standard, but is not av
Page 287 and 288:
efused HDCT. Of 23 patients, 20 com
Page 289 and 290:
we identified 49 and 220 patients w
Page 291 and 292:
879 TREATMENT OF PATIENTS WITH META
Page 293 and 294:
Median overall survival (OS) was 26
Page 295 and 296:
abstracts Genitourinary tumors, pro
Page 297 and 298:
and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300:
Working Group (PCWG)-2 guidelines r
Page 301 and 302:
atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304:
We observed tumor responses and pro
Page 305 and 306:
Here we report emerging data from t
Page 307 and 308:
928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310:
Disclosure: S. Oudard: Has acted as
Page 311 and 312:
939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314:
945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316:
952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318:
managed in a multidisciplinary (MD)
Page 319 and 320:
or hypercalcemia at screening; prio
Page 321 and 322:
meeting. The prevalence of LGSC is
Page 323 and 324:
Table: 975PD Continued AMG 386 + pa
Page 325 and 326:
physicians in the U.S. and Europe.
Page 327 and 328:
989P PHASE II STUDY OF COMBINATION
Page 329 and 330:
elated with stage, nodal involvemen
Page 331 and 332:
1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334:
eight patients who had infertility
Page 335 and 336: abstracts head and neck cancer 1016
Page 337 and 338: same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340: induction chemotherapy in the treat
Page 341 and 342: patients. We have developed a rando
Page 343 and 344: evaluated by the screening instrume
Page 345 and 346: morbidities that radiation would le
Page 347 and 348: Conclusions: Through adequate selec
Page 349 and 350: abstracts hematological malignancie
Page 351 and 352: anthracyclines in vitro. A favorabl
Page 353 and 354: 1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356: than the standard target of ≥2.5
Page 357 and 358: Patients: From November 2002 to May
Page 359 and 360: lymphadenopathy and multiple cutane
Page 361 and 362: prospective non-interventional stud
Page 363 and 364: Funding: GSK Biologicals Disclosure
Page 365 and 366: survival rates of 13-25% (Prieto et
Page 367 and 368: high response rates and prolonged p
Page 369 and 370: GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372: advisor for Merck Sharp & Dohme, an
Page 373 and 374: or cutaneous melanoma. A survival u
Page 375 and 376: systemic therapy or were intolerant
Page 377 and 378: abstracts neuroendocrine tumors and
Page 379 and 380: morbidity, with G3 tumors behaving
Page 381 and 382: pts. Poorly differentiated endocrin
Page 383 and 384: Adenocarcinoma was present in 25 pa
Page 385: Method: Endobronchial ultrasound gu
Page 389 and 390: disease after surgery were treated
Page 391 and 392: stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394: 1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396: Patients and methods: The study was
Page 397 and 398: months (95% CI:13-25). The PFS and
Page 399 and 400: maintenance therapy had favourable
Page 401 and 402: abstracts non-small cell lung cance
Page 403 and 404: Ingelheim, GSK Biologicals (compens
Page 405 and 406: 1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408: GlaxoSmithKline (myself, compensate
Page 409 and 410: 1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412: N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414: 1255P POPULATION BASED EVALUATION O
Page 415 and 416: 1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418: 1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420: MERCK SERONO: Advisor, speaker in s
Page 421 and 422: Conclusions: These data from SAiL a
Page 423 and 424: NSCLC diagnosis and time of BM diag
Page 425 and 426: 1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428: Network utilization of WBCGF in the
Page 429 and 430: 1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432: Results: The patients’ characteri
Page 433 and 434: EGFR mut at exons 18, 19, 21, and K
Page 435 and 436: Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556:
author index De Droogh E. ix452 (13
Page 557 and 558:
author index Esposito G. ix209 (618
Page 559 and 560:
author index Geiges G. ix306 (930P)
Page 561 and 562:
author index Hartono S. ix70 (155P)
Page 563 and 564:
author index Iwasaki H. ix542 (1694
Page 565 and 566:
author index Kodaira M. ix90 (228P)
Page 567 and 568:
author index Lichtensztejn D. ix350
Page 569 and 570:
author index Martinez A. ix496 (153
Page 571 and 572:
author index Morishita N. ix432 (13
Page 573 and 574:
author index Okamoto N. ix432 (1320
Page 575 and 576:
author index Piau S. ix456 (1401P)
Page 577 and 578:
author index Rodríguez Rodríguez
Page 579 and 580:
author index Scoggins C.R. ix371 (1
Page 581 and 582:
author index Stern L. ix272 (823P)
Page 583 and 584:
author index Trypaki M. ix429 (1308
Page 585 and 586:
author index Whitmore J.B. ix310 (9
Page 587 and 588:
subject index subject index A AAV-H
Page 589 and 590:
subject index ix115 (316TiP), ix116
Page 591 and 592:
subject index diffuse large B-cell
Page 593 and 594:
subject index (1033P), ix340 (1036P
Page 595 and 596:
subject index medical information,
Page 597 and 598:
subject index (612P), ix214 (633),
Page 599 and 600:
subject index RCC, ix274 (830P) re-
Page 601 and 602:
subject index TR-FRET, ix84 (206P)
Page 603 and 604:
drug index drug index 1248P, 1250P,
Page 605 and 606:
translational research index transl
Page 607 and 608:
Page 609:
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?